Navigation Links
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
Date:6/1/2008

eline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com .

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the future development and potential efficacy of XL184 and the timing of the initiation of pivotal trials for XL184. Words such as "hope," "plan," "continue," "will," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of XL184 to demonstrate safety and efficacy in clinical testing, our ability to initiate and complete pivotal trials for XL184 at the referenced times; the timing and level of expenses associated with the growth of proprietary programs and other collaborations; the therapeutic and commercial value of XL184 and our other compounds; our relationship with our partners; and our ability to enter into new collaborations, continue existing collaborations and receive milestones and royalties under our collaborative agreements. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 28, 2008, and other filings with the Securities and Exchange Commission. We exp
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Astellas ... director of Business Communications & Advocacy, Urology in ... Business Communications & Advocacy Margaret Long. In this role, ... to urology to patient and advocacy organizations, as ... on key strategic initiatives. Noland,s appointment is the ...
(Date:9/16/2014)... 16, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... commencing an underwritten registered public offering of shares ... are being offered by Aratana Therapeutics. ... joint book-running managers for the offering.  ...
(Date:9/16/2014)... 16, 2014 /PRNewswire-iReach/ -- Dan York has ... manufacturer of the RTD ® Advanced Wound Care ... its sales presence in the U.S. Under York,s leadership, ... direct field sales representatives in new sales territories that ... to add up to 20 sales representatives in major ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... June 2 Today In the Face of ... help pain management advocates expand their outreach efforts through popular ... to social media applications, such as Facebook, and walks users ... communication vehicles. Topics include "An Overview of Social Media," "Advocacy ...
... , JERUSALEM , June ... of oral drug delivery systems, announced,today that its subsidiary Oramed ... Ltd. ("Laser Detect"), an Israeli company listed on,the Tel Aviv ... be,called Entera Bio Ltd. ("Entera"). Under the terms of the ...
Cached Medicine Technology:In the Face of Pain® Offers Social Media 101 for Pain Management Advocates 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3
(Date:9/16/2014)... 2014 An experienced review website, ... and announced that Bluehost and HostGator.com are among ... want to purchase high quality web hosting (including ... visit their websites now. , BlueHost ( ... established itself as a reliable and long-standing force ...
(Date:9/16/2014)... Spring, Md. (PRWEB) September 16, 2014 Pulmonary ... Road , Free Education Forum for PH Patients and Families ... Pulmonary Hypertension Association – the country’s leading pulmonary hypertension association ... hypertension (PH) – a disease of the lungs that affects ... heart failure. Without treatment, mean survivability is only 2.8 years. ...
(Date:9/16/2014)... 17, 2014 Today, Top10BestSEOHosting.com ... from the USA and announces that HostMonster, ... the best Windows web hosting companies in ... worldwide clients high quality WordPress hosting (including ... , HostMonster provides outstanding customer support ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... routinely spot human papillomavirus (HPV), which is linked to the ... study shows that testing urine for HPV has good accuracy ... HPV," said lead researcher Dr. Neha Pathak. She is a ... Mary University of London, England. The test could be ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2
... today at 10:00 a.m. EST by calling, ... the Web at: http://www.airproducts.com/Invest/financialnews/EarningsReleases.htm ... Products,(NYSE: APD ) today reported net income of ... for its fiscal first quarter ended December 31,2007. Net ...
... DEERFIELD, Ill., Jan. 23 Astellas Pharma Inc. ... (FDA) has approved their,Supplemental New Drug Application (sNDA) ... for Injection in the treatment of patients,with Candidemia, ... approved in 2005 for the treatment of patients ...
... NDA Approval for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), ... for the Prevention ... Preterm Birth in Singleton Pregnancies, ST. LOUIS, Jan. ... specialty pharmaceutical company that,develops, manufactures, acquires and markets technology-differentiated,branded ...
... Advanced Therapy, HOLLYWOOD, Fla., Jan. 22 ... clot-busting drugs may succeed with more,advanced therapies that ... data being presented at the 20th annual International ... fail to improve with standard intravenous (IV),stroke therapy ...
... Calif., Jan. 22 Coherent, Inc.,(Pink Sheets: COHR), today ... market close and host a live webcast to discuss,its ... 7,2008 at 4:30 p.m. ET., The call will ... accessed,at either http://www.coherent.com/Investors/ or http://www.earnings.com .,For ...
... boy,s body is taken to the cleaners with the hospital ... Worth,couple has filed a lawsuit against Huguley Memorial Medical Center ... cleaners with the,hospital laundry., On July 8, 2007, Kourtney ... did not survive and his body was taken to the,hospital ...
Cached Medicine News:Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 2Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 3Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 4Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 5Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 6Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 7Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 8Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 9Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 10Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 11Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 12Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 13Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 14Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 15Health News:Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance 16Health News:FDA Approves Additional Indication for Astellas' MYCAMINE(R) 2Health News:FDA Approves Additional Indication for Astellas' MYCAMINE(R) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 4Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 5Health News:Stroke Undertreated 2Health News:Stroke Undertreated 3Health News:A Fort Worth Couple Sues Huguley Memorial Medical Center 2
200 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Inquire...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Inquire...
Medicine Products: